Table 2.
Primary outcome efficacy measures (baseline and week 4 and 12 weeks after treatment initiation) for MC treatment.
| Rating scale | Baseline | 4 weeks† | 12 weeks‡ | |||||
|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Baseline to 4-week change p value (Friedman two-way analysis) | Mean | SD | Baseline to 12-week change p value (Friedman two-way analysis) | |
| YGTSS-TS | 25.3 | 10.5 | 17.0 | 10.7 | 0.003∗ | 16.4 | 10.1 | 0.002∗ |
| YGTSS-I | 35.0 | 11.0 | 25.0 | 7.9 | 0.248 | 21.0 | 10.0 | 0.013∗ |
| YGTSS-Total | 60.3 | 17.1 | 42.0 | 13.3 | 0.032∗ | 37.4 | 14.6 | 0.001∗ |
| PUTS | 22.9 | 5.5 | 19.4 | 6.7 | 0.043∗ | 18.3 | 7.4 | 0.043∗ |
| Subjective percentage of tic improvement following treatment | — | — | 50.0 | 23.8 | — | 53.9 | 28.8 | — |
† N = 12, 3 subjects failed to complete midtrial evaluation, 3 subjects terminated the trial prematurely. ‡N = 15; ∗statistically significant. Abbreviations: MC: medical cannabis; YGTSS-TS: Yale Global Tic Severity Scale Tic Score; TGYSS-I: Yale Global Tic Severity Scale Impairment; PUTS: Premonitory Urge for Tic Scale; SD: standard deviation.